PMID: 15332625Aug 31, 2004Paper

Hydrophilic matrices to be used as bioactive and degradable bone cements

Journal of Materials Science. Materials in Medicine
Luciano F Boesel, Rui L Reis

Abstract

Two different hydrophilic systems were investigated regarding their suitability to be used as enzymatically degradable and highly bioactive bone cements. They contained either acrylic acid (AA) or 2-hydroxyethyl methacrylate (HEMA) as the hydrophilic monomer. Swelling, degradation, mechanical and bioactivity tests were employed to characterise their behaviour. Although both of the systems were very hydrophilic, only the one containing HEMA was able to form an apatite-like layer on its surface. Moreover, this system could be degraded by amylolytic enzymes at a rate easily controlled by the incorporation of different amounts of enzyme to the formulation, as shown by the evolution of the mechanical properties, weight loss and glucose concentration in the solution. These results show these novel systems have a great potential to induce bone ingrowth inside the pores created during the degradation of the material, therefore establishing a strong interface with the tissue.

Citations

Jan 31, 2012·Journal of Materials Science. Materials in Medicine·Ana C MendesRui L Reis
Dec 15, 2006·Acta Biomaterialia·Luciano F BoeselRui L Reis
Sep 11, 2016·Materials Science & Engineering. C, Materials for Biological Applications·Céline Aubrun-FillâtrePhilippe Hivart
Jun 26, 2007·Journal of Biomedical Materials Research. Part B, Applied Biomaterials·Gladius Lewis
Sep 17, 2008·ChemMedChem·Steven R MeyersMark W Grinstaff
May 8, 2015·Science and Technology of Advanced Materials·Anja C PaulyLukas J Scherer
Sep 23, 2020·Journal of the Mechanical Behavior of Biomedical Materials·Océane LyDenis Damidot

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.